OncoMatch/Clinical Trials/NCT05642455
SPEARHEAD-3 Pediatric Study
Is NCT05642455 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for synovial sarcoma.
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Neuroblastoma
Osteosarcoma
Biomarker criteria
Required: HLA-A A*02 positive
HLA-A*02 positive
Required: MAGEA4 expression
Tumor shows MAGE-A4 expression confirmed by central laboratory.
Excluded: HLA-A A*02:05 positive
Positive for HLA-A*02:05 in either allele; or any A*02 having same protein sequence as HLA-A*02:05
Demographics
Prior therapy
Must have received: systemic chemotherapy
Must have previously received a systemic chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health · Bethesda, Maryland
- Dana Farber Cancer Institute · Boston, Massachusetts
- Washington University · St Louis, Missouri
- Memorial Sloan Kettering Kids · New York, New York
- Duke University School of Medicine · Durham, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05642455 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic chemotherapy.
Does this trial require HLA-A?
Yes, HLA-A A*02 positive is a required biomarker for enrollment.
Does this trial require MAGEA4?
Yes, MAGEA4 expression is a required biomarker for enrollment.
Are patients with HLA-A alterations eligible?
No. HLA-A A*02:05 positive is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages